Related Articles
Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies
Epigenetic treatment‑mediated modulation of PD‑L1 predicts potential therapy resistance over response markers in myeloid malignancies: A molecular mechanism involving effectors of PD‑L1 reverse signaling
The anti-leukemic effect and molecular mechanisms of novel hydroxamate and benzamide histone deacetylase inhibitors with 5-aza-cytidine
The HDAC inhibitor, panobinostat, induces apoptosis by suppressing the expresssion of specificity protein 1 in oral squamous cell carcinoma
MEK/ERK and PI3K/AKT pathway inhibitors affect the transformation of myelodysplastic syndrome into acute myeloid leukemia via H3K27me3 methylases and de‑methylases